Ascendis Pharma Reports Q2 2025 Financial Results
Ticker: ASND · Form: 6-K · Filed: Aug 7, 2025 · CIK: 1612042
Sentiment: neutral
Topics: financial-results, quarterly-report, sec-filing
TL;DR
Ascendis Pharma dropped Q2 2025 earnings report on 8/7/25.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on August 7, 2025, to report its financial results for the fiscal quarter ended June 30, 2025. The filing includes a press release detailing these results.
Why It Matters
This filing provides investors with crucial financial performance data for Ascendis Pharma A/S for the second quarter of 2025, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial results filing and does not introduce new risks.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- June 30, 2025 (date) — Fiscal quarter end date
- August 7, 2025 (date) — Filing date
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is being filed to report the financial results of Ascendis Pharma A/S for the fiscal quarter ended June 30, 2025.
When was this Form 6-K filed?
This Form 6-K was filed on August 7, 2025.
What period do the reported financial results cover?
The financial results reported cover the fiscal quarter ended June 30, 2025.
What is the principal executive office address for Ascendis Pharma A/S?
The address of the principal executive offices is Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
Does Ascendis Pharma A/S file annual reports under Form 20-F or 40-F?
Ascendis Pharma A/S files annual reports under Form 20-F.
Filing Stats: 224 words · 1 min read · ~1 pages · Grade level 13.5 · Accepted 2025-08-07 16:05:24
Filing Documents
- d61138d6k.htm (6-K) — 9KB
- d61138dex991.htm (EX-99.1) — 125KB
- g61138g32r60.jpg (GRAPHIC) — 2KB
- g61138g89g88.jpg (GRAPHIC) — 4KB
- 0001193125-25-175420.txt ( ) — 143KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: August 7, 2025 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer